BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18804038)

  • 1. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
    Hallett WHD; Ames E; Álvarez M; Barao I; Taylor PA; Blazar BR; Murphy WJ
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1088-1099. PubMed ID: 18804038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
    Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
    J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
    Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
    Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40.
    Chen Y; Sun R; Wu X; Cheng M; Wei H; Tian Z
    J Innate Immun; 2016; 8(1):30-42. PubMed ID: 26067079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model.
    Hong H; Gu Y; Zhang H; Simon AK; Chen X; Wu C; Xu XN; Jiang S
    Clin Exp Immunol; 2010 Jan; 159(1):93-9. PubMed ID: 19817769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.
    Leong JW; Chase JM; Romee R; Schneider SE; Sullivan RP; Cooper MA; Fehniger TA
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):463-73. PubMed ID: 24434782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
    Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
    J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
    Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
    Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.
    Alvarez M; Bouchlaka MN; Sckisel GD; Sungur CM; Chen M; Murphy WJ
    J Immunol; 2014 Aug; 193(4):1709-16. PubMed ID: 25000978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody.
    Vignali D; Gürth CM; Pellegrini S; Sordi V; Sizzano F; Piemonti L; Monti P
    Transplantation; 2016 Sep; 100(9):1853-61. PubMed ID: 27306531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.
    Brenu EW; Bartley TJ; Wright CM; Hamilton-Williams EE
    Immunol Cell Biol; 2017 Oct; 95(9):803-813. PubMed ID: 28611472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
    Biron CA; Young HA; Kasaian MT
    J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.